DelveInsight’s “Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the OCD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obsessive Compulsive Disorder Market Forecast

 

Some of the key facts of the Obsessive Compulsive Disorder Market Report: 

• The Obsessive Compulsive Disorder market size was valued approximately USD 11,00 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In 2023, the market size of Obsessive Compulsive Disorder in the United States was approximately USD 600 million.

• In 2023, selective serotonin reuptake inhibitors (SSRIs) generated roughly USD 290 million in revenue across the seven major markets, while antipsychotics followed, earning around USD 160 million.

• In 2023, the market size for Obsessive Compulsive Disorder in the EU4 countries and the UK was approximately USD 380 million.

• In 2023, the United States had approximately 2.1 million diagnosed prevalent cases of Obsessive Compulsive Disorder.

• In 2023, the 7MM had around 320,000 mild cases, 760,000 moderate cases, and 1,100,000 severe cases of Obsessive Compulsive Disorder.

• In 2023, approximately 22% of Obsessive Compulsive Disorder cases in the EU4 and the UK were male, while about 78% were female.

• Key Obsessive Compulsive Disorder Companies: Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Pfizer, and others

• Key Obsessive Compulsive Disorder Therapies: Troriluzole, Fluvoxamine maleate, BHV-4157, Troriluzole, Quetiapine, Reclaim®, Bitopertin, topiramate, Escitalopram, Duloxetine, Topiramate, Paliperidone, pregabalin, and others

• The Obsessive Compulsive Disorder epidemiology based on gender analyzed that the occurrence of gender-specific cases of Obsessive Compulsive Disorder is more in females than in males

• The Obsessive Compulsive Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obsessive Compulsive Disorder pipeline products will significantly revolutionize the Obsessive Compulsive Disorder market dynamics. 

 

Obsessive Compulsive Disorder Overview

Obsessive-Compulsive Disorder (OCD) is a mental health condition characterized by persistent, unwanted thoughts (obsessions) and repetitive behaviors (compulsions) performed to alleviate anxiety. These behaviors often interfere with daily activities and can significantly impact an individual’s quality of life. Common obsessions include fears of contamination or harm, while compulsions might involve excessive cleaning, checking, or organizing. OCD affects both adults and children and typically requires treatment through therapy, medication, or a combination of both to manage symptoms effectively.

 

Get a Free sample for the Obsessive Compulsive Disorder Market Report –

https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market

 

Obsessive Compulsive Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Obsessive Compulsive Disorder Epidemiology Segmentation:

The Obsessive Compulsive Disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Obsessive Compulsive Disorder

• Prevalent Cases of Obsessive Compulsive Disorder by severity

• Gender-specific Prevalence of Obsessive Compulsive Disorder

• Diagnosed Cases of Episodic and Chronic Obsessive Compulsive Disorder

 

Download the report to understand which factors are driving Obsessive Compulsive Disorder epidemiology trends @ Obsessive Compulsive Disorder Epidemiology Forecast

 

Obsessive Compulsive Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obsessive Compulsive Disorder market or expected to get launched during the study period. The analysis covers Obsessive Compulsive Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Obsessive Compulsive Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Obsessive Compulsive Disorder Therapies and Key Companies

• Troriluzole: Biohaven Pharmaceuticals, Inc.

• Fluvoxamine maleate: AbbVie

• BHV-4157: Biohaven Pharmaceuticals, Inc.

• Quetiapine: AstraZeneca

• Reclaim®: MedtronicNeuro

• Bitopertin: Hoffmann-La Roche

• topiramate: Ortho-McNeil Pharmaceutical

• Escitalopram: Forest Laboratories

• Duloxetine: Eli Lilly and Company

• Topiramate: Janssen-Ortho Inc

• Paliperidone: Ortho-McNeil Janssen Scientific

• pregabalin: Pfizer

 

Discover more about therapies set to grab major Obsessive Compulsive Disorder market share @ Obsessive Compulsive Disorder Treatment Market

 

Obsessive Compulsive Disorder Market Drivers

• Negative lifestyle practices like unhealthy eating habits,smoking, lack of abundant sleep, and sedentary routine further proliferate anxiety disorders among individuals.

• Even though the emerging pipeline for OCD is not robust, the expected approval of troriluzole, a late-stage drug candidate with novel MoA, would drive the market.

 

Obsessive Compulsive Disorder Market Barriers

• SRIs, antipsychotics, mood stabilizers, and CBT are the mainstay of treatment for OCD. Therapies with novel MoAs are required to exhibit better efficacy and fewer side effects.

• Although several clinical, environmental, and biological predictors of response have been reported, delivering more personalized treatments for OCD is not a reality thus far. 

 

Scope of the Obsessive Compulsive Disorder Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Obsessive Compulsive Disorder Companies: Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Pfizer, and others

• Key Obsessive Compulsive Disorder Therapies: Troriluzole, Fluvoxamine maleate, BHV-4157, Troriluzole, Quetiapine, Reclaim®, Bitopertin, topiramate, Escitalopram, Duloxetine, Topiramate, Paliperidone, pregabalin, and others

• Obsessive Compulsive Disorder Therapeutic Assessment: Obsessive Compulsive Disorder current marketed and Obsessive Compulsive Disorder emerging therapies

• Obsessive Compulsive Disorder Market Dynamics: Obsessive Compulsive Disorder market drivers and Obsessive Compulsive Disorder market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Obsessive Compulsive Disorder Unmet Needs, KOL’s views, Analyst’s views, Obsessive Compulsive Disorder Market Access and Reimbursement 

 

To know more about Obsessive Compulsive Disorder companies working in the treatment market, visit @ Obsessive Compulsive Disorder Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Obsessive Compulsive Disorder Market Report Introduction

2. Executive Summary for Obsessive Compulsive Disorder

3. SWOT analysis of Obsessive Compulsive Disorder

4. Obsessive Compulsive Disorder Patient Share (%) Overview at a Glance

5. Obsessive Compulsive Disorder Market Overview at a Glance

6. Obsessive Compulsive Disorder Disease Background and Overview

7. Obsessive Compulsive Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Obsessive Compulsive Disorder 

9. Obsessive Compulsive Disorder Current Treatment and Medical Practices

10. Obsessive Compulsive Disorder Unmet Needs

11. Obsessive Compulsive Disorder Emerging Therapies

12. Obsessive Compulsive Disorder Market Outlook

13. Country-Wise Obsessive Compulsive Disorder Market Analysis (2020–2034)

14. Obsessive Compulsive Disorder Market Access and Reimbursement of Therapies

15. Obsessive Compulsive Disorder Market Drivers

16. Obsessive Compulsive Disorder Market Barriers

17.  Obsessive Compulsive Disorder Appendix

18. Obsessive Compulsive Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/